183 related articles for article (PubMed ID: 21955327)
1. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.
Xie G; Nie T; Mackenzie GG; Sun Y; Huang L; Ouyang N; Alston N; Zhu C; Murray OT; Constantinides PP; Kopelovich L; Rigas B
Br J Pharmacol; 2012 Apr; 165(7):2152-66. PubMed ID: 21955327
[TBL] [Abstract][Full Text] [Related]
2. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
Mackenzie GG; Ouyang N; Xie G; Vrankova K; Huang L; Sun Y; Komninou D; Kopelovich L; Rigas B
Cancer Prev Res (Phila); 2011 Jul; 4(7):1052-60. PubMed ID: 21464038
[TBL] [Abstract][Full Text] [Related]
3. Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
Mackenzie GG; Sun Y; Huang L; Xie G; Ouyang N; Gupta RC; Johnson F; Komninou D; Kopelovich L; Rigas B
Gastroenterology; 2010 Oct; 139(4):1320-32. PubMed ID: 20600034
[TBL] [Abstract][Full Text] [Related]
4. The ocular pharmacokinetics and biodistribution of phospho-sulindac (OXT-328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery.
Wen Z; Muratomi N; Huang W; Huang L; Ren J; Yang J; Persaud Y; Loloi J; Mallangada N; Kung P; Honkanen R; Rigas B
Int J Pharm; 2019 Feb; 557():273-279. PubMed ID: 30597269
[TBL] [Abstract][Full Text] [Related]
5. Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles.
Zhu R; Cheng KW; Mackenzie G; Huang L; Sun Y; Xie G; Vrankova K; Constantinides PP; Rigas B
Pharm Res; 2012 Nov; 29(11):3090-101. PubMed ID: 22723123
[TBL] [Abstract][Full Text] [Related]
6. Phospho-Sulindac (OXT-328) Inhibits Dry Eye Disease in Rabbits: A Dose-, Formulation- and Structure-Dependent Effect.
Huang W; Wen Z; Saglam MS; Huang L; Honkanen RA; Rigas B
J Ocul Pharmacol Ther; 2021; 37(6):321-330. PubMed ID: 34152861
[No Abstract] [Full Text] [Related]
7. Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.
Huang L; Zhu C; Sun Y; Xie G; Mackenzie GG; Qiao G; Komninou D; Rigas B
Carcinogenesis; 2010 Nov; 31(11):1982-90. PubMed ID: 20627873
[TBL] [Abstract][Full Text] [Related]
8. Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology.
Wong CC; Cheng KW; Papayannis I; Mattheolabakis G; Huang L; Xie G; Ouyang N; Rigas B
Pharm Res; 2015 May; 32(5):1663-75. PubMed ID: 25392229
[TBL] [Abstract][Full Text] [Related]
9. Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats.
Mattheolabakis G; Mackenzie GG; Huang L; Ouyang N; Cheng KW; Rigas B
Pharm Res; 2013 Jun; 30(6):1471-82. PubMed ID: 23483440
[TBL] [Abstract][Full Text] [Related]
10. Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: an in vitro study.
Schnitzler M; Dwight T; Robinson BG
Gut; 1996 May; 38(5):707-13. PubMed ID: 8707116
[TBL] [Abstract][Full Text] [Related]
11. Deactivation of sulindac-sulphide by human renal microsomes.
Eriksson LO; Boström H
Pharmacol Toxicol; 1988 Apr; 62(4):177-83. PubMed ID: 3133648
[TBL] [Abstract][Full Text] [Related]
12. The in vitro metabolism of phospho-sulindac amide, a novel potential anticancer agent.
Xie G; Cheng KW; Huang L; Rigas B
Biochem Pharmacol; 2014 Sep; 91(2):249-55. PubMed ID: 25044307
[TBL] [Abstract][Full Text] [Related]
13. Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics.
Cheng KW; Wong CC; Mattheolabakis G; Xie G; Huang L; Rigas B
Int J Oncol; 2013 Sep; 43(3):895-902. PubMed ID: 23807084
[TBL] [Abstract][Full Text] [Related]
14. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
[TBL] [Abstract][Full Text] [Related]
15. Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety.
Xie G; Wong CC; Cheng KW; Huang L; Constantinides PP; Rigas B
Br J Pharmacol; 2012 Sep; 167(1):222-32. PubMed ID: 22489789
[TBL] [Abstract][Full Text] [Related]
16. Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine.
Lawson KR; Ignatenko NA; Piazza GA; Cui H; Gerner EW
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1155-62. PubMed ID: 11097222
[TBL] [Abstract][Full Text] [Related]
17. Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer.
Cheng KW; Mattheolabakis G; Wong CC; Ouyang N; Huang L; Constantinides PP; Rigas B
Int J Oncol; 2012 Oct; 41(4):1199-203. PubMed ID: 22842609
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
McLaren CE; Fujikawa-Brooks S; Chen WP; Gillen DL; Pelot D; Gerner EW; Meyskens FL
Cancer Prev Res (Phila); 2008 Dec; 1(7):514-21. PubMed ID: 19139001
[TBL] [Abstract][Full Text] [Related]
19. Sulindac oxidation/reduction by microbial cultures; microbial models of mammalian metabolism.
Davis PJ; Guenthner LE
Xenobiotica; 1985 Oct; 15(10):845-57. PubMed ID: 4072250
[TBL] [Abstract][Full Text] [Related]
20. Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.
Wong CC; Cheng KW; Xie G; Zhou D; Zhu CH; Constantinides PP; Rigas B
J Pharmacol Exp Ther; 2012 Feb; 340(2):422-32. PubMed ID: 22085648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
